| View |
|
DRP-13056-02
|
Losartan Potassium
|
Episartan
|
50 mg
|
Tablet
|
Angiotensin II Receptor Blocker (ARB)
|
Kopran Limited
|
India
|
CLIDP Conversion
|
04 August 2024
|
23 November 2027
|
| View |
|
DRP-13058-01
|
Clotrimazole
|
Clofer
|
10 mg/g (1% w/w)
|
Topical Cream
|
Antifungal
|
Opal Laboratories (Pvt.) Limited
|
Pakistan
|
CLIDP Conversion
|
25 July 2024
|
23 November 2027
|
| View |
|
DRP-13209-07
|
Pregabalin
|
Nervolife
|
75 mg
|
Capsule
|
Antiepileptic
|
Titan Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
04 August 2024
|
29 December 2027
|
| View |
|
DRP-13431-01
|
Cefepime (as hydrochloride)
|
Centrapime-500
|
500 mg
|
Powder for Injection (IM/IV)
|
Antibacterial (Cephalosporin)
|
Swiss Parenterals Ltd.
|
India
|
CLIDP Conversion
|
06 August 2024
|
17 February 2028
|
| View |
|
DRP-13475-07
|
Ipratropium bromide + Salbutamol (as sulfate)
|
Sethair Duo
|
500 mcg/2.5 mg
|
Solution for Inhalation
|
Adrenergic in combination with anticholinergic
|
Legency Remedies Pvt. Ltd.
|
India
|
CLIDP Conversion
|
06 August 2024
|
27 February 2028
|
| View |
|
DRP-13578-04
|
Moxifloxacin (as hydrochloride)
|
Sensomox
|
5 mg/mL (0.5% w/v)
|
Ophthalmic Solution
|
Antiinfective (Fluoroquinolone)
|
Makcur Laboratories Limited
|
India
|
CLIDP Conversion
|
03 August 2024
|
13 March 2028
|
| View |
|
DRP-13681-03
|
Ursodeoxycholic Acid
|
None
|
300 mg
|
Film-Coated Tablet
|
Bile and Liver Therapy (Bile acids and derivative)
|
Sapphire Lifesciences Pvt. Ltd
|
India
|
CLIDP Conversion
|
04 August 2024
|
24 March 2028
|
| View |
|
DRP-13712-07
|
Moxifloxacin (as hydrochloride) + Dexamethasone phosphate (as sodium)
|
ModexCare
|
5 mg/1 mg per mL (0.5% w/v / 0.1% w/v)
|
Ophthalmic Solution
|
Anti-infective (Fluoroquinolone) / Corticosteroid
|
Makcur Laboratories Limited
|
India
|
CLIDP Conversion
|
25 July 2024
|
30 March 2028
|
| View |
|
DRP-14019-05
|
Co-Amoxiclav
|
Orcomox-S
|
457 mg / 5 mL
|
Powder for Suspension
|
Antibacterial (Penicillin)
|
Indchemie Health Specialities Private Limited
|
India
|
CLIDP Conversion
|
04 August 2024
|
06 June 2028
|
| View |
|
DRP-14029-03
|
Pantoprazole (as sodium sesquihydrate) + Domperidone (as maleate)
|
None
|
40 mg/30 mg
|
Modified Release Capsule
|
Proton Pump Inhibitor/ Propulsive
|
Sapphire Lifesciences Pvt. Ltd.
|
India
|
CLIDP Conversion
|
04 August 2024
|
07 June 2028
|
| View |
|
DRP-14049-01
|
Omeprazole
|
Peptobloc
|
20 mg
|
Capsule
|
Proton Pump Inhibitor
|
Medico Remedies Limited
|
India
|
CLIDP Conversion
|
06 August 2024
|
08 June 2028
|
| View |
|
DRP-14050-01
|
Ketoanalogues and Essential Amino Acids
|
Ketotech
|
(See reverse for formulation)
|
Film-Coated Tablet
|
Renal Nutrition therapy
|
Globela Pharma Private Limited
|
India
|
CLIDP Conversion
|
04 August 2024
|
08 June 2028
|
| View |
|
DRP-14215-03
|
Iron (as Iron sucrose)
|
Sucrufer
|
20 mg/mL
|
Solution for Injection (IV)
|
Anti-anemic Preparation
|
Maxitech Pharma (Pvt.) Ltd.
|
Pakistan
|
CLIDP Conversion
|
04 August 2024
|
27 July 2028
|
| View |
|
DRP-14239-01
|
Pantoprazole (as sodium sesquihydrate)
|
Pantotrek
|
40 mg
|
Lyophilized Powder for Injection (IV)
|
Proton Pump Inhibitor
|
Reyoung Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
04 August 2024
|
02 August 2028
|
| View |
|
DRP-14531-02
|
Febuxostat
|
Febuxipro
|
80 mg
|
Film-Coated Tablet
|
Anti-gout (Preparation Inhibiting Uric Acid Production)
|
Innova Captab Ltd. (Unit II)
|
India
|
CLIDP Conversion
|
25 July 2024
|
03 October 2028
|
| View |
|
DRP-14531-03
|
Febuxostat
|
Amfebb-80
|
80 mg
|
Film-Coated Tablet
|
Anti-gout (Preparation Inhibiting Uric Acid Production)
|
Innova Captab Limited
|
India
|
CLIDP Conversion
|
04 August 2024
|
03 October 2028
|
| View |
|
DRP-14532-02
|
Febuxostat
|
Febdiaff-40
|
40 mg
|
Film-Coated Tablet
|
Anti-gout (Preparation Inhibiting Uric Acid Production)
|
Innova Captab Limited
|
India
|
CLIDP Conversion
|
03 August 2024
|
03 October 2028
|
| View |
|
DRP-14532-04
|
Febuxostat
|
Amfebb-40
|
40 mg
|
Film-Coated Tablet
|
Anti-gout (Preparation Inhibiting Uric Acid Production)
|
Innova Captab Ltd. (Unit II)
|
India
|
CLIDP Conversion
|
04 August 2024
|
03 October 2028
|
| View |
|
DRP-14564-01
|
Fusidic acid + Betamethasone (as valerate)
|
Fusifer-B
|
20 mg/1mg per gram
|
Topical Cream
|
Antibacterial/Corticosteroid
|
Nabiqasim Industries (Private) Limited
|
Pakistan
|
CLIDP Conversion
|
25 July 2024
|
16 October 2028
|
| View |
|
DRP-14605-02
|
Apixaban
|
Elixaban
|
2.5 mg
|
Film-Coated Tablet
|
Anti-thrombotic Agent (Direct Factor Xa Inhibitor)
|
Baroque Pharmaceuticals Pvt. Ltd.
|
India
|
CLIDP Conversion
|
07 August 2024
|
27 October 2028
|